![Insights from 2024 EHA Annual Meeting](http://media.vumedi.com/thumbs/channel_logo/2024/6/8d846ca9-a80f-4328-885e-a4302b90cd59.png.200x0_q85.png)
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: SEQUOIA Trial Arm D - Zanubrutinib + Venetoclax for Treatment-Naïve CLL/SLL With Del(17p) and/or TP53
By
Insights from 2024 EHA Annual Meeting
FEATURING
Paolo Ghia
By
Insights from 2024 EHA Annual Meeting
FEATURING
Paolo Ghia
Login to view comments.
Click here to Login